Express Scripts Holding Company Forecasted to Earn FY2017 Earnings of $7.04 Per Share (ESRX)

Express Scripts Holding Company (NASDAQ:ESRX) – Analysts at Jefferies Group boosted their FY2017 earnings per share estimates for Express Scripts in a research report issued on Friday. Jefferies Group analyst B. Tanquilut now expects that the company will post earnings of $7.04 per share for the year, up from their previous forecast of $7.02. Jefferies Group currently has a “Buy” rating and a $80.00 target price on the stock. Jefferies Group also issued estimates for Express Scripts’ Q4 2017 earnings at $2.08 EPS, Q1 2018 earnings at $1.48 EPS, Q2 2018 earnings at $1.88 EPS, Q3 2018 earnings at $2.10 EPS, Q4 2018 earnings at $2.30 EPS and FY2018 earnings at $7.77 EPS.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.90. The firm had revenue of $24.68 billion for the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 EPS.

Several other equities research analysts have also weighed in on the stock. TheStreet raised shares of Express Scripts from a “c+” rating to a “b-” rating in a report on Monday, December 4th. ValuEngine raised shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Monday, December 4th. Deutsche Bank initiated coverage on shares of Express Scripts in a report on Monday, December 4th. They issued a “buy” rating and a $75.00 target price on the stock. Zacks Investment Research raised shares of Express Scripts from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a report on Monday, October 16th. Finally, BidaskClub raised shares of Express Scripts from a “hold” rating to a “buy” rating in a report on Thursday. Five equities research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $74.40.

Shares of Express Scripts (NASDAQ:ESRX) opened at $71.55 on Monday. The stock has a market cap of $40,523.99, a price-to-earnings ratio of 10.46, a price-to-earnings-growth ratio of 1.06 and a beta of 0.88. The company has a quick ratio of 0.61, a current ratio of 0.73 and a debt-to-equity ratio of 0.86. Express Scripts has a fifty-two week low of $55.80 and a fifty-two week high of $73.42.

A number of institutional investors have recently added to or reduced their stakes in the business. Dodge & Cox lifted its position in Express Scripts by 25.7% during the 2nd quarter. Dodge & Cox now owns 36,188,517 shares of the company’s stock valued at $2,310,275,000 after purchasing an additional 7,388,021 shares during the period. Macquarie Group Ltd. lifted its position in Express Scripts by 8.4% during the 2nd quarter. Macquarie Group Ltd. now owns 11,880,919 shares of the company’s stock valued at $758,480,000 after purchasing an additional 922,406 shares during the period. Northern Trust Corp lifted its position in Express Scripts by 12.2% during the 2nd quarter. Northern Trust Corp now owns 11,068,777 shares of the company’s stock valued at $706,629,000 after purchasing an additional 1,206,980 shares during the period. Veritas Asset Management LLP lifted its position in Express Scripts by 5.6% during the 3rd quarter. Veritas Asset Management LLP now owns 8,652,910 shares of the company’s stock valued at $547,902,000 after purchasing an additional 460,338 shares during the period. Finally, Nordea Investment Management AB lifted its position in Express Scripts by 2.6% during the 3rd quarter. Nordea Investment Management AB now owns 7,304,973 shares of the company’s stock valued at $462,551,000 after purchasing an additional 188,528 shares during the period. Institutional investors own 88.44% of the company’s stock.

In related news, CEO Timothy C. Wentworth purchased 8,000 shares of Express Scripts stock in a transaction that occurred on Tuesday, October 31st. The shares were acquired at an average price of $61.13 per share, for a total transaction of $489,040.00. Following the transaction, the chief executive officer now directly owns 98,628 shares in the company, valued at $6,029,129.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Phyllis S. Anderson sold 643 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $62.37, for a total transaction of $40,103.91. The disclosure for this sale can be found here. 0.68% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.truebluetribune.com/2017/12/18/express-scripts-holding-company-forecasted-to-earn-fy2017-earnings-of-7-04-per-share-esrx.html.

About Express Scripts

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Earnings History and Estimates for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply